A nice post by Digitel over on Stockhouse today regarding some possible milestones/catalysts/events coming up soon.

----------------------------------------------------

It often gets very quiet before BANG. Tailwinds is calling it a self-imposed quiet period by the new President and CEO. What may be next? The roll-out of the BTI story under new President and CEO from $4 billion annual company.

1. Filing with regulators to proceed with Phase Zero trial for Herceptin. The MD&A said trials are ready to begin. 
2. Name of clinical trial investigator.
3. Revealed for the first time the preclinical data package for Transcedpep-Herceptin including survival data.
4. Revealed for the first time the Phase Zero trial design and how quickly answers may be forthcoming as BTI targets $9 billion annual market and to become standard of care incorporating an already approved drug. Rob said the financing would allow for "extremely valuable" information. What will the market view as subjective probability of ultimate success after successful Phase Zero trial given $9 billion annual market?
5. Filing with regulators to proceed with trial for Lysosomal Storage Disease under renoud Scarpa bringing recognition to this program and platform.
6. Additional data from LSD program this anticipated this month in the MD&A.
7. Road show by Mark Day as he tells the world about the opportunity?

biOasis CEO, Dr. Mark Day, commented, "I consider the biOasis Transcend Platform to be one of the most unique and promising blood-brain barrier technologies of our time. Ensuring that experimental medicines are able to reach their targets in the brain has been shown to improve their probability of success. The development of neurotherapeutics has always been limited by the inability to get drugs across the blood-brain barrier. In fact, it's been nearly impossible to develop drugs that have both the right chemical structures to target CNS diseases, and to have, at the same time, structures that allow them to cross the blood-brain barrier. The two objectives are often completely incompatible."

"The Transcend Platform may finally give the pharmaceutical industry the ability to design neurotherapeutics with the knowledge that, no matter a drug's chemical structure, the Transcend peptide can likely be used get it across the blood-brain barrier in a very natural and cost-effective manner. The unmet medical needs for this are huge."